insiderdelta
CoverageForm 410-K10-Q8-K13D13G13F

PCSA · Processa Pharmaceuticals, Inc. - Financials

Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.

Price · PCSA

1Y3Y5YMax
Sign in to download
AnnualQuarterly

Income Statement

Line itemQ1 '26Q4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23
Revenue----------
Cost of Revenue----------
Gross Profit----------
R&D$1.81M-$1.66M$2.45M$1.59M-$2.29M$1.73M$1.54M-
SG&A$1.52M-$1.83M$1.50M$1.26M-$1.14M$1.35M$1.27M-
Total Operating Expenses----------
D&A$301---$301---$139-
Operating Income($3.33M)-($3.49M)($3.95M)($2.85M)-($3.42M)($3.08M)($2.81M)-
Interest Expense----------
Income Tax----------
Net Income($3.38M)-($3.44M)($3.93M)($2.83M)-($3.38M)($3.01M)($2.73M)-
EPS - Basic($1.29)-($1.75)($6.25)($7.50)-($25.75)($25.25)($27.75)-
EPS - Diluted($1.29)-($1.75)($6.25)($7.50)-($25.75)($25.25)($27.75)-

Balance Sheet

Line itemQ1 '26Q4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23
Cash & Equivalents$1.69M$5.54M$6.31M$6.94M$2.90M$1.19M$2.89M$5.57M$8.92M$4.71M
Accounts Receivable----------
Inventory----------
Accounts Payable$840.4K$1.06M$727.2K$785.8K$552.6K$880.9K$711.7K$953.1K$455.4K$311.6K
Current Assets$1.94M$5.67M$6.59M$7.15M$3.76M$1.87M$4.84M$7.48M$9.80M$5.63M
Total Assets$4.52M$7.81M$7.58M$8.18M$4.81M$3.23M$4.94M$7.60M$9.94M$5.79M
Current Liabilities$1.98M$2.24M$1.75M$2.07M$1.28M$1.53M$1.22M$1.55M$1.01M$730.6K
Long-term Debt----------
Total Liabilities$1.98M$2.24M$1.75M$2.07M$1.28M$1.53M$1.22M$1.58M$1.06M$797.5K
Stockholders' Equity$2.54M$5.58M$5.83M$6.11M$3.53M$1.70M$3.72M$6.02M$8.88M$4.99M
Retained Earnings($104.16M)($100.78M)($97.42M)($93.99M)($90.05M)($87.22M)($84.49M)($81.11M)($78.10M)($75.37M)

Cash Flow

Line itemQ1 '26Q4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23
Operating Cash Flow($3.59M)---($2.73M)---($2.05M)-
Investing Cash Flow($500.0K)---------
Financing Cash Flow$244.8K---$4.44M---$6.26M-
CapEx----------
Free Cash Flow----------

Ratios

MetricQ1 '26Q4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23
Profitability
Gross margin----------
Operating margin----------
EBITDA margin----------
Net margin----------
Free cash flow margin----------
FCF / Net income----------
R&D / Revenue----------
SG&A / Revenue----------
Effective tax rate----------
Return on assets-74.7%--45.3%-48.1%-58.9%--68.5%-39.6%-27.4%-
Return on equity-132.9%--58.9%-64.4%-80.4%--91.0%-50.0%-30.7%-
Return on invested capital----------
Liquidity
Current ratio0.982.543.763.452.931.223.974.829.707.71
Quick ratio0.982.543.763.452.931.223.974.829.707.71
Cash ratio0.852.483.603.342.260.782.373.598.836.44
Leverage
Debt / Equity----------
Debt / Assets----------
Debt / EBITDA----------
Interest coverage----------
Equity multiplier1.781.401.301.341.361.901.331.261.121.16
Liabilities / Assets0.440.290.230.250.270.470.250.210.110.14
Efficiency
Asset turnover----------
Inventory turnover----------
Days sales outstanding----------
Days inventory outstanding----------
Days payable outstanding----------
Cash conversion cycle----------
Valuation
P / E----------
P / B2.6x-39.1x13.1x25.0x-30.2x27.7x16.4x-
P / S----------
EV / EBITDA----------
Growth
Revenue growth (YoY)----------
Revenue CAGR (3y)----------
Revenue CAGR (5y)----------
Gross profit growth (YoY)----------
Operating income growth (YoY)-17.0%--1.9%-28.2%-1.3%--58.0%-13.5%31.6%-
Net income growth (YoY)-19.1%--1.5%-30.7%-4.0%--62.6%-15.2%32.2%-
EPS growth (YoY)82.8%-93.2%75.2%73.0%--32087.5%-7790.6%--
EPS CAGR (3y)----------
EPS CAGR (5y)----------
FCF growth (YoY)----------
FCF CAGR (5y)----------
Book value growth (YoY)-28.0%228.8%56.8%1.4%-60.3%-66.0%-48.1%-34.2%-12.4%-33.2%

Peer comparison

Same SIC group: Pharmaceutical Preparations

CompanyRevenue (last FY)Net marginROE
LLY$65.18B31.7%77.8%
UTHR$3.18B41.9%18.8%
PFE$62.58B12.4%9.0%
ZTS$9.47B28.2%80.2%
VRTX$12.00B32.9%21.2%

Comparing Processa Pharmaceuticals against the 5 most active filers in the same SIC group.